Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia (Q57402860)

J. Tiihonen

2

0 references

Katri Räikkönen-Talvitie

K. Räikkönen

8

0 references

Clive Osmond

C. Osmond

7

0 references

Per Eriksson

9

J. Eriksson

0 references

author name string

H. Wildgust

3

0 references

M. Beary

4

0 references

R. Hodgson

5

0 references

E. Kajantie

Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants

6

0 references

language of work or name

English

0 references

publication date

12 March 2012

0 references

published in

Psychological Medicine

0 references

volume

42

0 references

issue

11

0 references

page(s)

2275-2285

0 references

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

The validity of hospital discharge register data on coronary heart disease in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Severe mental illness and mortality of hospitalized ACS patients in the VHA

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

The validity of schizophrenia diagnosis in the Finnish Hospital Discharge Register: findings from a 10-year birth cohort sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Differential medication adherence among patients with schizophrenia and comorbid diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Infant Growth and Stroke in Adult Life

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Twenty-five year mortality of a community cohort with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Do deficits in cardiac care influence high mortality rates in schizophrenia? A systematic review and pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Revascularisation and mortality rates following acute coronary syndromes in people with severe mental illness: comparative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Accuracy of register-based schizophrenia diagnoses in a genetic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Validation of stroke diagnosis in the National Hospital Discharge Register and the Register of Causes of Death in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

The validity of death certificates: routine validation of death certification and its effects on mortality statistics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Excess heart-disease-related mortality in a national study of patients with mental disorders: identifying modifiable risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Accuracy of register- and record-based bipolar I disorder diagnoses in Finland; a study of twins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Lifetime prevalence of psychotic and bipolar I disorders in a general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Cigarette smoking and mortality risk in people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Inequalities in the primary care of patients with coronary heart disease and serious mental health problems: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Are there modifiable risk factors which will reduce the excess mortality in schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Schizophrenia and increased risks of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

The validation of the Finnish Hospital Discharge Register and Causes of Death Register data on stroke diagnoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

The fetal and childhood growth of persons who develop type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Cause-specific excess deaths associated with underweight, overweight, and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Quality of medical care and excess mortality in older patients with mental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Mental disorders and use of cardiovascular procedures after myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Treatment of ischaemic heart disease and stroke in individuals with psychosis under universal healthcare

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Growth and living conditions in childhood and hypertension in adult life: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

7 January 2021

Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

7 January 2021

Mortality in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

7 January 2021

Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

7 January 2021

Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1017%2FS0033291712000396

7 January 2021